Matches in Wikidata for { <http://www.wikidata.org/entity/Q105789235> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q105789235 description "clinical trial" @default.
- Q105789235 description "ensayo clínico" @default.
- Q105789235 description "ensayu clínicu" @default.
- Q105789235 description "klinisch onderzoek" @default.
- Q105789235 description "клінічне випробування" @default.
- Q105789235 description "临床试验" @default.
- Q105789235 name "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 name "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 type Item @default.
- Q105789235 label "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 label "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 prefLabel "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 prefLabel "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 P1132 Q105789235-2128E4C6-10F6-4D91-8425-AFBA266D56BD @default.
- Q105789235 P1476 Q105789235-12DD68C7-65D3-4DBC-9F1F-CAADE21FDCED @default.
- Q105789235 P17 Q105789235-F45EAC9C-D5BB-4C22-BCBA-629803A86CF4 @default.
- Q105789235 P2899 Q105789235-83EE8EE8-CEE7-45F3-A67A-4E5D7C1AD7DD @default.
- Q105789235 P3098 Q105789235-7FD65759-C517-4F5C-9824-D2AB6B83D0B0 @default.
- Q105789235 P31 Q105789235-4E927335-DC0F-44F8-B49A-2D9AF3D08FC4 @default.
- Q105789235 P4135 Q105789235-755611F3-3C1C-4490-90BE-D7D483952727 @default.
- Q105789235 P4844 Q105789235-21A573E2-8152-425E-87B0-C7CBF35F98D0 @default.
- Q105789235 P4844 Q105789235-E705EA8C-F77C-4F0B-A750-33F325498C54 @default.
- Q105789235 P580 Q105789235-04BC91B7-F2ED-4B01-83AC-FAF26526D2FA @default.
- Q105789235 P582 Q105789235-83D094C4-2486-4650-B73E-43601C30C10B @default.
- Q105789235 P6099 Q105789235-AED54F5C-89A1-4ACF-9808-E7235F203926 @default.
- Q105789235 P8005 Q105789235-C2DA647D-B02C-49FB-AC14-0ED48401CAB1 @default.
- Q105789235 P8363 Q105789235-11D01E45-AA72-4594-A5CF-85ACC485C953 @default.
- Q105789235 P921 Q105789235-3907128B-FE77-4B1B-9C54-EC7CA718D6FF @default.
- Q105789235 P1132 "+34" @default.
- Q105789235 P1476 "A Pivotal, Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q105789235 P17 Q41 @default.
- Q105789235 P2899 "+18" @default.
- Q105789235 P3098 "NCT04564456" @default.
- Q105789235 P31 Q30612 @default.
- Q105789235 P4135 "+60" @default.
- Q105789235 P4844 Q1002165 @default.
- Q105789235 P4844 Q27264747 @default.
- Q105789235 P580 "2020-09-22T00:00:00Z" @default.
- Q105789235 P582 "2020-10-31T00:00:00Z" @default.
- Q105789235 P6099 Q5452194 @default.
- Q105789235 P8005 Q76651189 @default.
- Q105789235 P8363 Q78089383 @default.
- Q105789235 P921 Q27264747 @default.